Neoantigens in cancer immunotherapy
TN Schumacher, RD Schreiber - Science, 2015 - science.org
The clinical relevance of T cells in the control of a diverse set of human cancers is now
beyond doubt. However, the nature of the antigens that allow the immune system to …
beyond doubt. However, the nature of the antigens that allow the immune system to …
[PDF][PDF] Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Tertiary lymphoid structures in cancer
TN Schumacher, DS Thommen - Science, 2022 - science.org
BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
Signatures of mutational processes in human cancer
All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …
processes generating these mutations is limited. The catalogue of somatic mutations from a …
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …
The human cell atlas
A Regev, SA Teichmann, ES Lander, I Amit, C Benoist… - elife, 2017 - elifesciences.org
The recent advent of methods for high-throughput single-cell molecular profiling has
catalyzed a growing sense in the scientific community that the time is ripe to complete the …
catalyzed a growing sense in the scientific community that the time is ripe to complete the …
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
The immune system influences the fate of developing cancers by not only functioning as a
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …
B cells and tertiary lymphoid structures promote immunotherapy response
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
M Chalabi, LF Fanchi, KK Dijkstra, JG Van den Berg… - Nature medicine, 2020 - nature.com
Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
Defining 'T cell exhaustion'
Abstract 'T cell exhaustion'is a broad term that has been used to describe the response of T
cells to chronic antigen stimulation, first in the setting of chronic viral infection but more …
cells to chronic antigen stimulation, first in the setting of chronic viral infection but more …